cicugaha.wordpress.com
June 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: today announced that , Chairman, Chief Executive Officer and Presidentof InterMune, will present at the Goldmajn Sachs 30th Annual Global Healthcare Conference in New York on June 9, 2009 at 2:35 p.m. ET. To accesse a live audio webcast ofthe presentation, investorsd and other interested parties may log on to the investot relations page of InterMune's corporatwe website at . The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to registerf or download anynecessary software.
InterMune is a biotechnology compangy focused onthe research, development and commercialization of innovativwe therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonaryfibrosis (IPF) and hepatitis C virus infections. The pulmonology portfolio includes the Phase3 program, which is evaluating pirfenidone as a possiblee therapeutic candidate for the treatment of patients with IPF, RECAP, an open-labelp extension study from CAPACITY and a research progra m focused on small molecules for the treatment of pulmonary The hepatology portfolio includes the HCV protease inhibitof compound ITMN-191 (referred to as R7227 at Roche, its development partner) in Phase 1b, a second-generation HCV protease inhibitotr research program, and a research program evaluating new targetse in hepatology.
For additional information about InterMune andits R&D please visit . SOURCE InterMune, Inc.
No comments:
Post a Comment